Cannabis Technologies, Inc. (C.CAN)

Cannabis-TechnologiesEntering the marijuana industry only earlier in 2014, Cannabis Technologies, Inc is a new player in the biopharmaceutical area of the industry. The Vancouver, Canada-based company is developing cannabis-based therapies, both botanical and non-botanical, to treat certain health conditions. Among these are glaucoma, arthritis, Huntington’s disease, epilepsy, diabetes, obesity, and cancer. These, however, are only the company’s initial focus.

Cannabis Technologies’ pipeline so far shows two products. One is CTI-085, a topical formulation made with a proprietary compound for treating glaucoma. The other is CTI-091, a proprietary mixture to provide relief from joint pain and arthritis-related swelling. Both formulations contain cannabinoids (which are compounds from the cannabis plant) and non-cannabis based active ingredients.

In developing its products, the company uses its proprietary bioinformatics tool called the Cannabinoid Drug Design Platform. It identifies individual cannabis compounds that can be used to target genes responsible for diseases.

Cannabis Technologies also has a botanical research team handling the breeding and cultivation of marijuana strains and clones. The team has set out to investigate not only the main cannabinoids THC and CBD, but also other pharmacologically active compounds in medicinal cannabis.

The company was originally a software and network services provider called Meridex Network Corp, which later became Meridex Software Corp. It was founded in 1981, but became Cannabis Technologies, Inc only in May 2014.

Today, Cannabis Technologies, Inc is traded in the Canadian Securities Exchange under the symbol CAN, and in OTC markets under the symbol CANLF. It has a market value of USD 7.29 M. Its company executives include Craig Schneider, President and CEO; Terese Giesleman, CFO; Dr. Sazzad Hossain, Chief Scientific Officer; and Dr. Hyder A. Khoja, Director of Botanical Research & Cultivation.


Yahoo! Finance: C.CAN News

Latest Financial News for C.CAN